Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz Z. et al
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-breast 3): A randomised, open-label, multicentre, phase 2 trial.

Lancet Oncol 2015;
16: 1700-10

Bibliographische Angaben herunterladen

Aufrufen in: